ArticleCancers2023
Accuracy of p16 IHC in Classifying HPV-Driven OPSCC in Different Populations.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advancements in immunotherapy for oropharyngeal cancer: Current landscape and future prospects.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2026Pooled it
- Article
- The importance of HPV testing in oropharyngeal cancer in two US populations.Neoplasia (New York, N.Y.) · 2026Article
- Nanomaterials for the Prevention, Detection, and Treatment of Pharyngeal Human Papillomavirus Infection: A Translational Roadmap.Materials (Basel, Switzerland) · 2026Review
- Detection of recurrence of HPV-driven oropharyngeal cancer by HPV cell-free DNA.Scientific reports · 2026Article
- HPV Status and Genotype Associations with Nodal Involvement and Treatment Strategy in Bulgarian Patients with Head and Neck Squamous Cell Carcinoma: A Prospective Multicenter Observational Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Tumour-infiltrating lymphocytes do not predict survival in human papillomavirus-associated oropharyngeal squamous cell carcinoma: a single institution retrospective review.The Journal of laryngology and otology · 2026Article
- HPV Detection in Oropharyngeal Cancer: A Narrative Review of Diagnostic and Emerging Molecular Approaches.Diagnostics (Basel, Switzerland) · 2026Review
- EGFRvIII expression in head and neck squamous cell carcinoma: clinical significance and sources of frequency variation across studies.Frontiers in oncology · 2026Review
- Resolving Clinically Indeterminate Findings During Anal Cancer Surveillance with TTMV-HPV DNA.Cancers · 2025Article
- Discordance Between p16-Expression and HPV-Status in Sinonasal Carcinoma: A Multicenter Retrospective Study.Cancers · 2025Article
- Molecular Insights into HPV-Driven Head and Neck Cancers: From Viral Oncoproteins to Precision Therapeutics.Viruses · 2025Review
- Transoral Robotic Surgery for the Salvage of Primarily Irradiated Oropharyngeal Squamous Cell Carcinomas Recurring at the Base of the Tongue: A Small Monoinstitutional Series.Journal of personalized medicine · 2025Article
- Circulating biomarkers in HPV-associated oropharyngeal cancer: Clinical applications of liquid biopsy in diagnosis, prognosis, and surveillance.The journal of liquid biopsy · 2025Review
- The Role of the Microbiome in Oropharyngeal Squamous Cell Carcinoma: A Systematic Review.Journal of personalized medicine · 2025Review
- Review
- A Bibliometric Analysis of HPV-Positive Oropharyngeal Squamous Cell Carcinoma from 2000 to 2023.Pathogens (Basel, Switzerland) · 2025Article
- Multi-omics insights into the molecular signature and prognosis of hypopharyngeal squamous cell carcinoma.Communications biology · 2025Article
- Performance analysis of Leica Biosystems p16 monoclonal antibody in oropharyngeal squamous cell carcinoma.Diagnostic pathology · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-risk human papillomavirus (HPV) infection is a defined etiopathogenetic factor in oropharyngeal carcinogenesis with a clear prognostic value. The P16 IHC (immunohistochemistry) is a widely accepted marker for HPV-driven carcinogenesis in oropharyngeal squamous cell carcinoma (OPSCC); in the present paper, we discuss its reliability as a standalone marker in different populations. The literature suggests that rates of p16 IHC false positive results are inversely correlated with the prevalence of HPV-driven carcinogenesis in a population. We propose a formula that can calculate such a false positive rate while knowing the real prevalence of HPV-driven OPSCCs in a given population. As it has been demonstrated that p16 positive/HPV negative cases (i.e., false positives at p16 IHC) have the same prognosis as p16 negative OPSCC, we conclude that despite the valuable prognostic value of p16 IHC, relying only on a p16 IHC positive result to recommend treatment de-intensification could be risky. For this aim, confirmation with an HPV nucleic acid detection system, especially in areas with a low prevalence of HPV-related OPSCCs, should be pursued.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.